

Nickolas Papadopoulos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1022151/publications.pdf>

Version: 2024-02-01

91
papers

26,617
citations

50170

46
h-index

49773

87
g-index

97
all docs

97
docs citations

97
times ranked

38020
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer Genome Landscapes. <i>Science</i> , 2013, 339, 1546-1558.	6.0	6,507
2	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. <i>Science Translational Medicine</i> , 2014, 6, 224ra24.	5.8	3,665
3	Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018, 359, 926-930.	6.0	1,872
4	Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i> . <i>Science</i> , 2011, 333, 1154-1157.	6.0	1,568
5	The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints. <i>Cancer Discovery</i> , 2015, 5, 43-51.	7.7	1,180
6	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. <i>Science Translational Medicine</i> , 2016, 8, 346ra92.	5.8	1,036
7	Vitamin C selectively kills <i>KRAS</i> and <i>BRAF</i> mutant colorectal cancer cells by targeting GAPDH. <i>Science</i> , 2015, 350, 1391-1396.	6.0	722
8	Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 21188-21193.	3.3	585
9	Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11774-11779.	3.3	578
10	Cancer-Associated Mutations in Endometriosis without Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 1835-1848.	13.9	451
11	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10202-10207.	3.3	438
12	Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. <i>JAMA Oncology</i> , 2019, 5, 1710.	3.4	383
13	A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts. <i>Gastroenterology</i> , 2015, 149, 1501-1510.	0.6	376
14	Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. <i>Science Translational Medicine</i> , 2015, 7, 293ra104.	5.8	372
15	Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. <i>Science</i> , 2020, 369, .	6.0	351
16	Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2261-2272.	13.9	337
17	Evaluating the evaluation of cancer driver genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 14330-14335.	3.3	325
18	Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9704-9709.	3.3	317

#	ARTICLE	IF	CITATIONS
19	Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. <i>Nature Genetics</i> , 2017, 49, 358-366.	9.4	316
20	CACP, encoding a secreted proteoglycan, is mutated in camptodactyly-arthropathy-coxa vara-pericarditis syndrome. <i>Nature Genetics</i> , 1999, 23, 319-322.	9.4	286
21	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. <i>Cancer Discovery</i> , 2016, 6, 166-175.	7.7	282
22	Evaluation of DNA from the Papanicolaou Test to Detect Ovarian and Endometrial Cancers. <i>Science Translational Medicine</i> , 2013, 5, 167ra4.	5.8	264
23	Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. <i>Nature Genetics</i> , 2014, 46, 1170-1172.	9.4	247
24	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , 2019, 68, 663-671.	6.1	234
25	Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-associated Colorectal Cancers. <i>Gastroenterology</i> , 2016, 150, 931-943.	0.6	208
26	The Early Detection of Pancreatic Cancer: What Will It Take to Diagnose and Treat Curable Pancreatic Neoplasia?. <i>Cancer Research</i> , 2014, 74, 3381-3389.	0.4	207
27	Targeting a neoantigen derived from a common TP53 mutation. <i>Science</i> , 2021, 371, .	6.0	194
28	Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 9846-9851.	3.3	178
29	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	178
30	Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. <i>Genes and Development</i> , 2015, 29, 2219-2224.	2.7	168
31	Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1118.	3.4	152
32	Applications of liquid biopsies for cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	151
33	Serial Assessment of Human Tumor Burdens in Mice by the Analysis of Circulating DNA. <i>Cancer Research</i> , 2007, 67, 9364-9370.	0.4	147
34	A multimodality test to guide the management of patients with a pancreatic cyst. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	129
35	The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. <i>Nature Biotechnology</i> , 2006, 24, 985-995.	9.4	124
36	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. <i>ELife</i> , 2018, 7, .	2.8	118

#	ARTICLE	IF	CITATIONS
37	Bispecific antibodies targeting mutant <i>RAS</i> neoantigens. <i>Science Immunology</i> , 2021, 6, .	5.6	106
38	Precancerous neoplastic cells can move through the pancreatic ductal system. <i>Nature</i> , 2018, 561, 201-205.	13.7	96
39	Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 15-24.	1.5	91
40	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003620.	3.9	88
41	Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4293-4300.	0.8	87
42	Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis. <i>Clinical Cancer Research</i> , 2015, 21, 1944-1950.	3.2	85
43	Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma. <i>Cancer Prevention Research</i> , 2016, 9, 265-274.	0.7	80
44	Targeting public neoantigens for cancer immunotherapy. <i>Nature Cancer</i> , 2021, 2, 487-497.	5.7	79
45	Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. <i>International Journal of Cancer</i> , 2021, 148, 1014-1026.	2.3	77
46	FAST-SeqS: A Simple and Efficient Method for the Detection of Aneuploidy by Massively Parallel Sequencing. <i>PLoS ONE</i> , 2012, 7, e41162.	1.1	65
47	Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival. <i>Nature Communications</i> , 2020, 11, 3644.	5.8	55
48	DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES. <i>Neuro-Oncology</i> , 2014, 16, iii7-iii7.	0.6	50
49	Assessing aneuploidy with repetitive element sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4858-4863.	3.3	50
50	Detection of aneuploidy in patients with cancer through amplification of long interspersed nucleotide elements (LINEs). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 1871-1876.	3.3	48
51	Frequent HIN-1 Promoter Methylation and Lack of Expression in Multiple Human Tumor Types. <i>Molecular Cancer Research</i> , 2004, 2, 489-494.	1.5	46
52	Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma. <i>Modern Pathology</i> , 2019, 32, 1544-1550.	2.9	45
53	Detection of Somatic TP53 Mutations in Tampons of Patients With High-Grade Serous Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2014, 124, 881-885.	1.2	44
54	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. , 2019, 7, 40.		42

#	ARTICLE	IF	CITATIONS
55	Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9967-9972.	3.3	41
56	Genetic Classification of Gliomas: Refining Histopathology. Cancer Cell, 2015, 28, 9-11.	7.7	40
57	Direct Detection and Quantification of Neoantigens. Cancer Immunology Research, 2019, 7, 1748-1754.	1.6	40
58	Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands. Nature Biotechnology, 2021, 39, 1220-1227.	9.4	40
59	Targeting loss of heterozygosity for cancer-specific immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	39
60	High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 427-434.	1.4	38
61	High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder. Modern Pathology, 2016, 29, 511-515.	2.9	34
62	A novel approach for selecting combination clinical markers of pathology applied to a large retrospective cohort of surgically resected pancreatic cysts. Journal of the American Medical Informatics Association: JAMIA, 2017, 24, 145-152.	2.2	34
63	Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. , 2021, 9, e002473.		33
64	Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. Human Pathology, 2016, 53, 8-13.	1.1	31
65	Diagnostic potential of tumor DNA from ovarian cyst fluid. ELife, 2016, 5, .	2.8	30
66	Genomic analysis identifies frequent deletions of Dystrophin in olfactory neuroblastoma. Nature Communications, 2018, 9, 5410.	5.8	30
67	TCR Î² chainâ€‘directed bispecific antibodies for the treatment of T cell cancers. Science Translational Medicine, 2021, 13, .	5.8	30
68	Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. Human Pathology, 2019, 85, 1-9.	1.1	28
69	Ultrasensitive detection of tumorâ€‘specific mutations in saliva of patients with oral cavity squamous cell carcinoma. Cancer, 2021, 127, 1576-1589.	2.0	27
70	Pathophysiology of ctDNA Release into the Circulation and Its Characteristics: What Is Important for Clinical Applications. Recent Results in Cancer Research, 2020, 215, 163-180.	1.8	26
71	Epigenetic remodelling and dysregulation of DLGAP4 is linked with early-onset cerebellar ataxia. Human Molecular Genetics, 2014, 23, 6163-6176.	1.4	19
72	Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).. Journal of Clinical Oncology, 2018, 36, 3516-3516.	0.8	19

#	ARTICLE	IF	CITATIONS
73	Molecular and Pathology Features of Colorectal Tumors and Patient Outcomes Are Associated with <i>Fusobacterium nucleatum</i> and Its Subspecies <i>animalis</i> . <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 210-220.	1.1	19
74	Massively Parallel Sequencing of Esophageal Brushings Enables an Aneuploidy-Based Classification of Patients With Barrett's Esophagus. <i>Gastroenterology</i> , 2021, 160, 2043-2054.e2.	0.6	17
75	Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. <i>Nature Communications</i> , 2021, 12, 5271.	5.8	17
76	An engineered antibody fragment targeting mutant β -catenin via major histocompatibility complex I neoantigen presentation. <i>Journal of Biological Chemistry</i> , 2019, 294, 19322-19334.	1.6	15
77	Bisulfite-converted duplexes for the strand-specific detection and quantification of rare mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 4733-4738.	3.3	12
78	Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 11015-11015.	0.8	10
79	Intraductal papillary mucinous neoplasm in a neonate with congenital hyperinsulinism and a de novo germline SKL gene mutation. <i>Pancreatology</i> , 2015, 15, 194-196.	0.5	8
80	Identification of novel noncoding transcripts in telomerase-negative yeast using RNA-seq. <i>Scientific Reports</i> , 2016, 6, 19376.	1.6	8
81	Multicancer early detection test: Preclinical, translational, and clinical evidence—generation plan and provocative questions. <i>Cancer</i> , 2022, 128, 861-874.	2.0	7
82	Circulating tumor DNA (ctDNA) in nonmetastatic colorectal cancer (CRC): Potential role as a screening tool.. <i>Journal of Clinical Oncology</i> , 2015, 33, 518-518.	0.8	6
83	Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2441-2453.	1.1	5
84	Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA100-LBA100.	0.8	5
85	Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16206-e16206.	0.8	4
86	Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma. <i>ELife</i> , 2022, 11, .	2.8	4
87	Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients. <i>Frontiers in Medicine</i> , 2022, 9, 849222.	1.2	2
88	An isogenic cell line panel for sequence-based screening of targeted anticancer drugs. <i>IScience</i> , 2022, 25, 104437.	1.9	2
89	Conversion Technology and Cancer Predispositions. , 2003, 223, 415-424.		0
90	GENE-01. THE MUTATIONAL LANDSCAPE OF PRIMARY CHORDOMAS AND THEIR SENSITIVE DETECTION IN PLASMA ctDNA BY MULTIPLE NEXT GENERATION SEQUENCING TECHNOLOGIES. <i>Neuro-Oncology</i> , 2019, 21, vi97-vi97.	0.6	0

#	ARTICLE	IF	CITATIONS
91	629â€¦Targeting a shared TP53 neoantigen with bispecific T cell retargeting antibody. , 2020, , .		0